Tobias Wollersheim

Tobias Wollersheim

Auto-generated profile, based on publicly available information

Tobias Wollersheim

Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2014 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
TWTobias Wollersheim
Tobias Wollersheim
JWJanine Woehlecke
Janine Woehlecke
MKMartin Krebs
Martin Krebs
JHJida Hamati
Jida Hamati
DLDoerte Lodka
Doerte Lodka
JFJens Fielitz
Jens Fielitz

15 February 2013 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
SWSteffen Weber-Carstens
Steffen Weber-Carstens
JSJoanna Schneider
Joanna Schneider
TWTobias Wollersheim
Tobias Wollersheim
AAAnke Assmann
Anke Assmann
JBJeffrey Bierbrauer
Jeffrey Bierbrauer
SSSimone Spuler
Simone Spuler
Rationale: Critical illness myopathy (CIM) has no known cause and no treatment. Immobilization and impaired glucose metabolism are implicated. Objectives: We assessed signal transduction in skeletal muscle of patients at risk for CIM. We also investigated the effects of evoked muscle contraction. Methods: In a prospective observational and interventional pilot study, we screened 874 mechanically ventilated patients with a sepsis-related organ-failure assessment score greater than or equal to 8 for 3 consecutive days in the first 5 days of intensive care unit stay. Thirty patients at risk for CIM underwent euglycemic-hyperinsulinemic clamp, muscle microdialysis studies, and muscle biopsies. Control subjects were healthy. In five additional patients at risk for CIM, we performed corresponding analyses after 12-day, daily, unilateral electrical muscle stimulation with the contralateral leg as control. Measurements and Main Results: We performed successive muscle biopsies and assessed systemic insulin sensitivity and signal transduction pathways of glucose utilization at the mRNA and protein level and glucose transporter-4 (GLUT4) localization in skeletal muscle tissue. Skeletal muscle GLUT4 was trapped at perinuclear spaces, most pronounced in patients with CIM, but resided at the sarcolemma in control subjects. Glucose metabolism was not stimulated during euglycemic-hyperinsulinergic clamp. Insulin signal transduction was competent up to p-Akt activation; however, p-adenosine monophosphate–activated protein kinase (p-AMPK) was not detectable in CIM muscle. Electrical muscle stimulation increased p-AMPK, repositioned GLUT4, locally improved glucose metabolism, and prevented type-2 fiber atrophy. Conclusions: Insufficient GLUT4 translocation results in decreased glucose supply in patients with CIM. Failed AMPK activation is involved. Evoked muscle contraction may prevent muscle-specific AMPK failure, restore GLUT4 disposition, and diminish protein breakdown. Clinical trial registered with http://www.controlled-trials.com (registration number ISRCTN77569430).

10 January 2014 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
SKSusanne Koch
Susanne Koch
TWTobias Wollersheim
Tobias Wollersheim
JBJeffrey Bierbrauer
Jeffrey Bierbrauer
KHKurt Haas
Kurt Haas
RMRudolf Mörgeli
Rudolf Mörgeli
SWSteffen Weber-Carstens
Steffen Weber-Carstens

20 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CLClaudia Langhans
Claudia Langhans
SWSteffen Weber-Carstens
Steffen Weber-Carstens
FSFranziska Schmidt
Franziska Schmidt
JHJida Hamati
Jida Hamati
MKMelanie Kny
Melanie Kny
JFJens Fielitz
Jens Fielitz
Systemic inflammation is a major risk factor for critical-illness myopathy (CIM) but its pathogenic role in muscle is uncertain. We observed that interleukin 6 (IL-6) and serum amyloid A1 (SAA1) expression was upregulated in muscle of critically ill patients. To test the relevance of these responses we assessed inflammation and acute-phase response at early and late time points in muscle of patients at risk for CIM. Prospective observational clinical study and prospective animal trial. Two intensive care units (ICU) and research laboratory. 33 patients with Sequential Organ Failure Assessment scores ≥8 on 3 consecutive days within 5 days in ICU were investigated. A subgroup analysis of 12 patients with, and 18 patients without CIM (non-CIM) was performed. Two consecutive biopsies from vastus lateralis were obtained at median days 5 and 15, early and late time points. Controls were 5 healthy subjects undergoing elective orthopedic surgery. A septic mouse model and cultured myoblasts were used for mechanistic analyses. Early SAA1 expression was significantly higher in skeletal muscle of CIM compared to non-CIM patients. Immunohistochemistry showed SAA1 accumulations in muscle of CIM patients at the early time point, which resolved later. SAA1 expression was induced by IL-6 and tumor necrosis factor-alpha in human and mouse myocytes in vitro. Inflammation-induced muscular SAA1 accumulation was reproduced in a sepsis mouse model. Skeletal muscle contributes to general inflammation and acute-phase response in CIM patients. Muscular SAA1 could be important for CIM pathogenesis. ISRCTN77569430.

23 April 2019 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
TWTobias Wollersheim
Tobias Wollersheim
JGJulius Grunow
Julius Grunow
NCNiklas M. Carbon
Niklas M. Carbon
KHKurt Haas
Kurt Haas
JMJohannes Malleike
Johannes Malleike
SWSteffen Weber-Carstens
Steffen Weber-Carstens
Background: Early mobilization improves physical independency of critically ill patients at hospital discharge in a general intensive care unit (ICU)‐cohort. We aimed to investigate clinical and molecular benefits or detriments of early mobilization and muscle activating measures in a high‐risk ICU‐acquired weakness cohort.Methods: Fifty patients with a SOFA score ≥9 within 72 h after ICU admission were randomized to muscle activating measures such as neuromuscular electrical stimulation or whole‐body vibration in addition to early protocol‐based physiotherapy (intervention) or early protocol‐based physiotherapy alone (control). Muscle strength and function were assessed by Medical Research Council (MRC) score, handgrip strength and Functional Independence Measure at first awakening, ICU discharge, and 12 month follow‐up. Patients underwent open surgical muscle biopsy on day 15. We investigated the impact of muscle activating measures in addition to early protocol‐based physiotherapy on muscle strength and function as well as on muscle wasting, morphology, and homeostasis in patients with sepsis and ICU‐acquired weakness. We compared the data with patients treated with common physiotherapeutic practice (CPP) earlier.Results: ICU‐acquired weakness occurs within the entire cohort, and muscle activating measures did not improve muscle strength or function at first awakening (MRC median [IQR]: CPP 3.3 [3.0–4.3]; control 3.0 [2.7–3.4]; intervention 3.0 [2.1–3.8];P > 0.05 for all), ICU discharge (MRC median [IQR]: CPP 3.8 [3.4–4.4]; control 3.9 [3.3–4.0]; intervention 3.6 [2.8–4.0];P > 0.05 for all), and 12 month follow‐up (MRC median [IQR]: control 5.0 [4.3–5.0]; intervention 4.8 [4.3–5.0];P = 0.342 for all). No signs of necrosis or inflammatory infiltration were present in the histological analysis. Myocyte cross‐sectional area in the intervention group was significantly larger in comparison with the control group (type I +10%; type IIa +13%; type IIb +3%;P < 0.001 for all) and CPP (type I +36%; type IIa +49%; type IIb +65%;P < 0.001 for all). This increase was accompanied by an up‐regulated gene expression for myosin heavy chains (fold change median [IQR]:MYH12.3 [1.1–2.7];MYH20.7 [0.2–1.8];MYH45.1 [2.2–15.3]) and an unaffected gene expression forTRIM63,TRIM62, andFBXO32.Conclusions: In our patients with sepsis syndrome at high risk for ICU‐acquired weakness muscle activating measures in addition to early protocol‐based physiotherapy did not improve muscle strength or function at first awakening, ICU discharge, or 12 month follow‐up. Yet it prevented muscle atrophy.

1 February 2018 in Clinical Nutrition
Verified
Journal Article
Closed access
TWT. Wollersheim
T. Wollersheim
SFS. Frank
S. Frank
MMM.C. Müller
M.C. Müller
VSV. Skrypnikov
V. Skrypnikov
NCN.M. Carbon
N.M. Carbon
SWSteffen Weber-Carstens
Steffen Weber-Carstens